Back to top
more

Otonomy, Inc. (OTIC)

(Delayed Data from NSDQ)

$2.82 USD

2.82
37,102

+0.02 (0.71%)

Updated May 3, 2019 03:59 PM ET

After-Market: $2.81 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

[OTIC]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Industry: Medical - Drugs

Record: 1

12/30/2022

Company Report

Pages: 4

Dropping Coverage Following Plan of Liquidation and Dissolution

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

08/02/2022

Company Report

Pages: 7

OTO-313 Tinnitus Phase 2 Misses, Is Discontinued; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

07/26/2022

Company Report

Pages: 9

2Q22 Results; Potentially Transformational OTO-313 Tinnitus Phase 2 Data In August; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

04/25/2022

Company Report

Pages: 8

Efficacy Signals Piling Up; OTO-413 Hearing Loss POC Bolstered; OTO-313 Tinnitus Phase 2 Data Mid-Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

03/01/2022

Company Report

Pages: 6

4Q21: Tinnitus Phase 2 Over-Enrolled Well Ahead of Schedule; That and Hearing Loss Data by Mid-Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

11/11/2021

Company Report

Pages: 6

3Q21: Tinnitus and Hearing Loss Validation by Mid-2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OTIC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

05/12/2021

Company Report

Pages: 7

1Q21: Broad Neurotology Pipeline Advancing; Potential Gamechanging Tinnitus and Hearing Loss Data Mid-22;

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

02/23/2021

Company Report

Pages: 6

Otividex Phase 3 Misses; Lowering PT to $5.50; Stock Undervalues Earlier-Stage Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

02/12/2021

Company Report

Pages: 7

Otividex Pivotal Data This Month; Underappreciated Earlier Pipeline an Exciting Insurance Policy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

12/18/2020

Company Report

Pages: 9

Positive Hearing Loss POC; Broader Neurotology Pipeline Gaining Credibility; Otividex Phase 3 Data 1Q21; PT up to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

11/16/2020

Company Report

Pages: 10

3Q20: On Cusp of Multiple Material Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

08/06/2020

Company Report

Pages: 11

2Q20: Pipeline Advancing; Pivotal Otividex Data Within 6 Months as Early-Stage Pipeline Ripens

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

07/07/2020

Company Report

Pages: 10

Positive Tinnitus POC; New Otividex Stats Plan; Raise to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

06/16/2020

Company Report

Pages: 7

Only Slightly Behind Estimates; Undervalued With Cash Runway Through Multiple Readouts

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

05/18/2020

Company Report

Pages: 10

COVID Delays Trials; Timing Update Expected Next Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

03/02/2020

Company Report

Pages: 9

4Q19 Results Demonstrate Financial Discipline; Multiple Pipeline Catalysts Within Months; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

11/06/2019

Company Report

Pages: 9

3Q19 Results; Deliberate Otividex Phase 3 Enrollment Means Data Slips a Quarter to 3Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

08/29/2019

Company Report

Pages: 29

Initiate with Buy and $8 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 75.00

Research Provided by a Third Party

// eof